HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION
AssigneeThe Rockefeller University
InventorsJeffrey V. Ravetch, Stylianos Bournazos
Life of this patent
Estimating the term…
Abstract
The present invention relates to human IgG Fc domain variants with improved effector function and uses thereof.
Claims20
A polypeptide comprising an Fc variant of a human IgG I Fc polypeptide, wherein the Fc variant comprises an Alanine (A) at position 236, a Leucine (L) at position 330, and a Glutamic acid (E) at position 332, and a Serine (S) at position 239, a Leucine (L) at position 428, and a Serine (S) at position 434, wherein the numbering is according to the EU index in Kabat, and wherein an antibody having the Fc variant has a half life comparable to the antibody having the wild-type IgG1 Fc sequence of SEQ ID NO:
- 1.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.